Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DISTOL-EXT: Oral treprostinil SR for digital ischemic lesions in scleroderma – open-label extension
2008-006978-15Phase 2Completed
- Sponsor
- United Therapeutics Corporation
- Start
- May 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of treprostinil in systemic sclerosis (SSc), scleroderma and digital ischemic lesion (DIL), sponsored by United Therapeutics Corporation. Primary endpoint: Long-term safety of treprostinil diethanolamine SR. Started May 2009; status: completed.
02
Drugs
treprostinil
03
Conditions
systemic sclerosis (SSc)sclerodermadigital ischemic lesion (DIL)
Beyond the preview
Go deeper on 2008-006978-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006978-15.